Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar NuclearSteve (< 20) Submitted: 12/15/2010 11:45:15 AM : Outperform Start Price: $57.77 CELG Score: +13.25

Great Margins and Revenue growth - price performance this year doesn't seem to reflect. Identified in my YCharts/FinViz double screen.

Featured Broker Partners


Advertisement